RESUMO
INTRODUCTION: Residual renal function (RRF) and phosphaturia had not stimulated particular interest in studies regarding patients on hemodialysis. In the current year the Authors have selected a series of patients with RRF undergoing infrequent hemodialysis treatments. PURPOSE: The Authors have carried out a study of the phosphate balance in patients on infrequent hemodialysis with the hypothesis that the phosphaturia was always neglected in hemodialysis patients, but it could represent a positive impact element on the cardiovascular events and mortality in hemodialysis. METHODS: During 6 months, the Authors have conducted forty urine collections in 10 patients on twice a week hemodialysis (TWH) (age: 69,3 years, dialysis vintage: 42,7 months and 40.9 months on TWH) and eighty urine collections in 8 patients on once a week hemodialysis and low-protein diet (CDDP) (age: 69.6 years, dialysis vintage: 24.7 months and 24 months in CDDP) to determine RRF and phosphaturia. We compared the balance of phosphate compared with a thrice-weekly hemodialysis considering on phosphate removal: dialysis efficiency, phosphate-binders power on the protein- phosphates intake and the extent of phosphaturia. RESULTS: The patients on infrequent hemodialysis have demonstrated a significant share of urinary phosphate output leading to a weekly phosphoric balance equal to zero or even negative. CONCLUSIONS: The phosphoric balance in infrequent hemodialysis patients is a decisive way to remove the phosphates, confirming that this factor could be decisive on the improved survival and reduced cardiovascular mortality compared to patients receiving thrice-weekly hemodialysis. The Authors stress again the need to keep as long as possible the FRR.
Assuntos
Hipofosfatemia Familiar/terapia , Falência Renal Crônica/fisiopatologia , Falência Renal Crônica/terapia , Diálise Renal/estatística & dados numéricos , Idoso , Feminino , Humanos , Hipofosfatemia Familiar/etiologia , Falência Renal Crônica/complicações , MasculinoRESUMO
HYPOTHESIS: Phosphorus and vitamin D (calcitriol) supplementation in the Phex mouse, a murine model for endolymphatic hydrops (ELH), will improve otic capsule mineralization and secondarily ameliorate the postnatal development of ELH and sensorineural hearing loss (SNHL). BACKGROUND: Male Phex mice have X-linked hypophosphatemic rickets (XLH), which includes osteomalacia of the otic capsule. The treatment for XLH is supplementation with phosphorus and calcitriol. The effect of this treatment has never been studied on otic capsule bone and it is unclear if improving the otic capsule bone could impact the mice's postnatal development of ELH and SNHL. METHODS: Four cohorts were studied: 1) wild-type control, 2) Phex control, 3) Phex prevention, and 4) Phex rescue. The control groups were not given any dietary supplementation. The Phex prevention group was supplemented with phosphorus added to its drinking water and intraperitoneal calcitriol from postnatal day (P) 7-P40. The Phex rescue group was also supplemented with phosphorus and calcium but only from P20 to P40. At P40, all mice underwent auditory brainstem response (ABR) testing, serum analysis, and temporal bone histologic analysis. Primary outcome was otic capsule mineralization. Secondary outcomes were degree of SNHL and presence ELH. RESULTS: Both treatment groups had markedly improved otic capsule mineralization with less osteoid deposition. The improved otic capsule mineralized did not prevent the development of ELH or SNHL. CONCLUSION: Supplementation with phosphorus and calcitriol improves otic capsule bone morphology in the Phex male mouse but does not alter development of ELH or SNHL.
Assuntos
Doenças Ósseas/terapia , Suplementos Nutricionais , Otopatias/terapia , Perda Auditiva Neurossensorial/terapia , Hipofosfatemia Familiar/terapia , Análise de Variância , Animais , Biópsia por Agulha , Doenças Ósseas/diagnóstico , Calcitriol/farmacologia , Modelos Animais de Doenças , Otopatias/diagnóstico , Hidropisia Endolinfática/diagnóstico , Hidropisia Endolinfática/terapia , Potenciais Evocados Auditivos do Tronco Encefálico , Perda Auditiva Neurossensorial/diagnóstico , Humanos , Hipofosfatemia Familiar/diagnóstico , Imuno-Histoquímica , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Mutantes , Fósforo/farmacologia , Distribuição Aleatória , Resultado do TratamentoRESUMO
It is largely agreed that preservation of residual kidney function (RKF) has a directly proportional affect on general, and in particular cardiovascular, mortality. During evaluation of patients on infrequent hemodialysis (ID) as both as once-weekly or twice-weekly hemodialysis it has been frequently underestimated the importance of phosphaturia, Indeed, the native kidney preserves the ability to eliminate not only toxic molecules but also a significative output of phosphate despite of a severe decrease of RKF. This task the modern membranes are as yet not very efficient of reproducing. The hemodialysis patients on ID who adhere accurately to a low protein diet of 0.6-0.8 g/kg/day could reach a draw in the balance of phosphates. In view of the significant impact produced by poor phosphate control on both RKF and the frequency of even severe cardiovascular effects, infrequent dialysis with its negative or neutral weekly phosphate balance, may constitute a valid "bridging" treatment even in the long-term, thus explaining the improved survival rates compared to patients receiving conventional triweekly hemodialysis.
Assuntos
Falência Renal Crônica/terapia , Rim/metabolismo , Fosfatos/metabolismo , Diálise Renal , Doenças Cardiovasculares/metabolismo , Doenças Cardiovasculares/terapia , Progressão da Doença , Trato Gastrointestinal/efeitos dos fármacos , Humanos , Hipofosfatemia Familiar/terapia , Rim/fisiopatologiaRESUMO
Rickets is an important problem in children. The majority of rickets in children is due to deficiency of calcium, phosphorus or vitamin D. However, rickets may also be a feature of renal diseases, e.g. renal tubular acidosis, hypophosphatemic rickets or rickets associated with renal insufficiency. The treatment varies with etiology and hence complete workup is essential before initiating therapy.
Assuntos
Acidose Tubular Renal/complicações , Azotemia/complicações , Hipofosfatemia Familiar/complicações , Raquitismo/etiologia , Acidose Tubular Renal/diagnóstico , Acidose Tubular Renal/terapia , Adolescente , Azotemia/diagnóstico , Azotemia/terapia , Análise Química do Sangue , Criança , Pré-Escolar , Feminino , Humanos , Hipercalciúria/complicações , Hipofosfatemia Familiar/diagnóstico , Hipofosfatemia Familiar/terapia , Índia , Lactente , Masculino , Raquitismo/diagnóstico , Raquitismo/terapia , Clima Tropical , Urinálise , Deficiência de Vitamina D/complicações , Deficiência de Vitamina D/diagnóstico , Deficiência de Vitamina D/terapiaAssuntos
Hipofosfatemia Familiar , 25-Hidroxivitamina D3 1-alfa-Hidroxilase/genética , Calcitriol/administração & dosagem , Cálcio/administração & dosagem , Diagnóstico Diferencial , Humanos , Hidroxicolecalciferóis/administração & dosagem , Hipofosfatemia Familiar/classificação , Hipofosfatemia Familiar/diagnóstico , Hipofosfatemia Familiar/etiologia , Hipofosfatemia Familiar/terapia , Mutação , Prognóstico , Receptores de Calcitriol/genéticaAssuntos
Cromossomos Humanos Par 12/genética , Fatores de Crescimento de Fibroblastos/genética , Genes Dominantes , Hipofosfatemia Familiar/genética , Diagnóstico Diferencial , Fator de Crescimento de Fibroblastos 23 , Humanos , Hipofosfatemia Familiar/diagnóstico , Hipofosfatemia Familiar/fisiopatologia , Hipofosfatemia Familiar/terapia , Mutação de Sentido Incorreto , PrognósticoAssuntos
Doenças Genéticas Ligadas ao Cromossomo X/genética , Hipofosfatemia Familiar/genética , Diagnóstico Diferencial , Fator de Crescimento de Fibroblastos 23 , Fatores de Crescimento de Fibroblastos/genética , Doenças Genéticas Ligadas ao Cromossomo X/diagnóstico , Doenças Genéticas Ligadas ao Cromossomo X/fisiopatologia , Doenças Genéticas Ligadas ao Cromossomo X/terapia , Humanos , Hidroxicolecalciferóis/administração & dosagem , Hipofosfatemia Familiar/diagnóstico , Hipofosfatemia Familiar/fisiopatologia , Hipofosfatemia Familiar/terapia , Glicoproteínas de Membrana/genética , Metaloendopeptidases/genética , Endopeptidase Neutra Reguladora de Fosfato PHEX , Fosfatos/administração & dosagem , PrognósticoRESUMO
This study reports the benefits and side effects of conventional treatment, phosphate and calcitriol supplementation in patients with heritable hypophosphatemic rickets and a long-term follow-up, median of 60.9 months. The group is composed of 17 patients (ten girls). Sixteen patients presented with bone pain and/or deformities, and in one patient the diagnosis was radiological. All the patients had increased alkaline phosphatase, hypophosphatemia, decreased fractional phosphate tubular reabsorption (TRP) and maximum tubular phosphate reabsorption/glomerular filtration rate ratio (TPO4/GFR). Ten of 17 patients had metabolic acidosis, which was corrected only with the conventional treatment. Potassium citrate was prescribed to the patients who developed hypercalciuria. Excluding one patient with pulmonary dysfunction, the remaining 16 patients were divided into two groups according to the age at treatment onset (T0): group I (GI) > or =4 years (n =9) and GII <4 years (n =7). GI and GII had similar follow-up periods and treatment protocols. Seven out of nine GI patients underwent orthopedic surgery, in contrast to none of GII. Anthropometric data results showed that within each group there is no difference in weight and stature z -score at T0 and at the end of the observation (Tf), but, when both groups are compared, GII shows higher z-score for stature at T0 (p <0.05) and at Tf (p <0.05). Nephrocalcinosis developed in three cases and correlated with hypercalciuria (p <0.001) and dose of calcitriol (p =0.03). In conclusion, higher stature z-score is associated with early treatment. A careful protocol is recommended to detect such complications as nephrocalcinosis. We suggest potassium citrate for patients with hypercalciuria to avoid calcium precipitation.
Assuntos
Hipofosfatemia Familiar/terapia , Pré-Escolar , Feminino , Seguimentos , Humanos , Lactente , Masculino , Fatores de TempoRESUMO
Hereditary hypophosphatemic rickets groups together X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemic rickets (ADHR) and hereditary hypophosphatemic rickets with hypercalciuria (HHRH, autosomal recessive). Clinical and biological characteristics and treatment depend on specific etiology. Mutations causing hereditary hypophosphatemic rickets involve PHEX located on Xp11.22 for XLH and FGF-23 located on 12p13 for ADHR. The gene involved in HHRH remains unknown: candidates may encode proteins that modulate phosphate transporter expression or activity. Others forms of rickets must be ruled out: acquired hypophosphatemia due to oncogenic osteomalacia, X-linked recessive hypophosphatemic rickets or Dent's disease, and hereditary 1, 25-dihydroxyvitamin D-resistant rickets with a defect either in the 1-alpha-hydroxylase gene (pseudo-vitamin D deficiency rickets, PDDR) or in the vitamin D receptor (hereditary vitamin D-resistant rickets, HVDRR).
Assuntos
Hipofosfatemia Familiar/diagnóstico , Hipofosfatemia Familiar/genética , Adulto , Diagnóstico Diferencial , Fator de Crescimento de Fibroblastos 23 , Humanos , Hipofosfatemia Familiar/fisiopatologia , Hipofosfatemia Familiar/terapia , MutaçãoAssuntos
Fatores de Crescimento de Fibroblastos/genética , Fatores de Crescimento de Fibroblastos/fisiologia , Hipofosfatemia Familiar/etiologia , Osteomalacia/etiologia , Animais , Calcitriol/metabolismo , Fator de Crescimento de Fibroblastos 23 , Humanos , Hipofosfatemia Familiar/diagnóstico , Hipofosfatemia Familiar/terapia , Túbulos Renais Proximais/metabolismo , Osteomalacia/diagnóstico , Osteomalacia/terapia , Síndromes Paraneoplásicas/etiologia , Fósforo/metabolismo , PrognósticoAssuntos
Fatores de Crescimento de Fibroblastos/genética , Hipofosfatemia Familiar/genética , Osteomalacia/genética , Animais , Calcitriol/administração & dosagem , Calcitriol/efeitos adversos , Fatores de Crescimento de Fibroblastos/fisiologia , Genes Dominantes , Humanos , Hipofosfatemia Familiar/fisiopatologia , Hipofosfatemia Familiar/terapia , Mutação , Osteomalacia/fisiopatologia , Osteomalacia/terapia , Fósforo/administração & dosagem , Fósforo/efeitos adversosRESUMO
This review was conducted to study the diagnosis, treatment, and growth progression in infants and adolescents with familial hypophosphatemic rickets. The bibliographic search was carried out utilizing the electronic databases MEDLINE, OVID, and LILACS and by direct research within the last 15 years using the keywords rickets, familial hypophosphatemia, vitamin D deficiency, stature growth, childhood, and adolescence. Article selection was done by comparing the evaluation of the growth in patients with familial hypophosphatemic rickets, including the variables that might affect them, for possible future therapeutic proposals. It is concluded that the most significant fact in the treatment of familial hypophosphatemic rickets in infancy was the magnitude of the final stature. The use of growth hormone can be helpful in these patients. However, research reporting treatments with the use of the growth hormone for rickets are controversial. The majority of the authors agree that treatment using vitamin D and phosphate enables some statural growth in cases of early diagnosis, reflecting a better prognosis.
Assuntos
Hipofosfatemia Familiar/fisiopatologia , Hipofosfatemia Familiar/terapia , Raquitismo/fisiopatologia , Raquitismo/terapia , Adolescente , Criança , Suscetibilidade a Doenças , Humanos , Hipofosfatemia Familiar/diagnóstico , Hipofosfatemia Familiar/genética , Raquitismo/diagnóstico , Raquitismo/genética , Fatores de TempoRESUMO
Rickets is caused by deficient mineralization at the level of growth plate and is usually due to a decreased serum calcium/phosphate product. Although the diagnosis of rickets can usually be suspected on the basis of a clinical examination (bone deformities in legs, impaired growth), radiological examination and detailed biochemical work-up are necessary to elucidate the etiology of the underlying disease. It is important to differentiate between calcipenic/vitamin deficient and phosphopenic rickets. The former is due to vitamin D deficiency, and the ultimate cause of this usually lies in altered vitamin D supply; however, impaired synthesis of or resistance to the actions of vitamin D can also be a cause. Phosphopenic rickets is usually related to impaired phosphate reabsorption in the proximal renal tubule. Both calcipenic and phosphopenic rickets can be acquired or hereditary in origin.
Assuntos
Hipofosfatemia Familiar/diagnóstico , Hipofosfatemia Familiar/terapia , Fosfatos/uso terapêutico , Raquitismo/diagnóstico , Raquitismo/terapia , Vitamina D/uso terapêutico , Diagnóstico Diferencial , Humanos , Guias de Prática Clínica como Assunto , Padrões de Prática MédicaRESUMO
It is well known that fibroblast growth factor (FGF) family members are associated with embryonic development and are critical for basic metabolic functions. This review will focus upon fibroblast growth factor-23 (FGF23) and its roles in disorders associated with phosphate handling. The discovery that mutations in FGF23 were responsible for the isolated renal phosphate wasting disorder autosomal dominant hypophosphatemic rickets (ADHR) has ascribed novel functions to the FGF family. FGF23 circulates in the bloodstream, and animal models demonstrate that FGF23 controls phosphate and Vitamin D homeostasis through the regulation of specific renal proteins. The ADHR mutations in FGF23 produce a protein species less susceptible to proteolytic processing. X-linked hypophosphatemic rickets (XLH), tumor-induced osteomalacia (TIO), and fibrous dysplasia of bone (FD) are disorders involving phosphate homeostasis that share phenotypes with ADHR, indicating that FGF23 may be a common denominator for the pathophysiology of these syndromes. Our understanding of FGF23 will help to develop novel therapies for phosphate wasting disorders, as well as for disorders of increased serum phosphate, such as tumoral calcinosis, a rare disorder, and renal failure, a common disorder.
Assuntos
Fatores de Crescimento de Fibroblastos/fisiologia , Homeostase/fisiologia , Hipofosfatemia Familiar/fisiopatologia , Fosfatos/metabolismo , Animais , Fator de Crescimento de Fibroblastos 23 , Fatores de Crescimento de Fibroblastos/genética , Displasia Fibrosa Óssea/genética , Humanos , Hipofosfatemia Familiar/genética , Hipofosfatemia Familiar/terapia , Mesenquimoma/complicações , Camundongos , Osteomalacia/etiologia , Endopeptidase Neutra Reguladora de Fosfato PHEX , Proteínas/genética , Proteínas/metabolismoRESUMO
Oncogenic hypophosphatemic osteomalacia (OHO) is an uncommon hypophosphatemic syndrome characterized by bone pain, proximal muscle weakness and rickets. It has been postulated that OHO results from overproduction of a humoral phosphaturic factor by an occult tumour. Recently, some OHO tumours have been shown to elaborate fibroblast growth factor-23 (FGF-23), which causes renal phosphate wasting when administered to mice. The purpose of this study was to undertake detailed investigations to confirm the diagnosis of OHO in a pediatric patient and to document the biochemical, radiographic and bone histological phenotype before and after tumour removal. We describe an 11-year-old, previously healthy girl with significant pain and functional disability associated with hypophosphatemic rickets. Circulating 1,25-(OH)(2) vitamin D was very low (14 pM; N: 40-140) while the FGF-23 serum level was markedly elevated [359.5 reference units (RU)/ml, N: 33-105]. An iliac bone biopsy revealed severe osteomalacia, but periosteocytic lesions, as are typical for X-linked hypophosphatemic rickets, were not seen. Sequence analyses of the PHEX and FGF23 genes were normal. A radiographic skeletal survey revealed a small exostosis of the left, distal ulnar metaphysis. A tumour was subsequently removed from this site and the pathology was consistent with benign, fibro-osseous tissue. Serum FGF-23 was normal when measured at 7 h post-operatively, while serum phosphate reached the low-normal range at 16 days following surgery. An iliac bone biopsy taken 5 months after the operation showed improvement, but not yet resolution, of the osteomalacia. Biochemical parameters of bone and mineral metabolism suggested that complete resolution of the osteomalacia was not achieved until 12 months following surgery. One year after tumour removal, the patient was pain-free and had resumed a normal level of activity. The rapid normalization of FGF-23 levels following removal of a benign tumour and the subsequent improvement in the biochemical and histological parameters of bone and mineral metabolism suggest that FGF-23 played a key role in this girl's disease.
Assuntos
Neoplasias Ósseas/cirurgia , Fatores de Crescimento de Fibroblastos/biossíntese , Hipofosfatemia Familiar/terapia , Ulna/patologia , Sequência de Bases , Neoplasias Ósseas/complicações , Neoplasias Ósseas/metabolismo , Criança , Primers do DNA , Feminino , Fator de Crescimento de Fibroblastos 23 , Humanos , Hipofosfatemia Familiar/etiologiaRESUMO
Hypophosphataemia does not necessarily indicate phosphate (Pi) depletion. In acute emergencies such as septicaemia, alkalosis or re-feeding, hypophosphataemia may result from redistribution of Pi from the extracellular to the intracellular space. Hypophosphataemia from true Pi depletion gives rise to skeletal (osteomalacia) and extraskeletal (myopathy, cardiomyopathy) disorders. It is practically never the result of diminished nutritional intake. The most severe syndromes of Pi depletion result from diminished tubular Pi re-absorption and renal Pi wasting. In the differential diagnosis mainly four conditions have to be considered: (i) tumour-associated osteomalacia, (ii) X-linked hypophosphataemia (XLH), (iii) autosomal dominant hypophosphataemia, and (iv) hypercalcaemic renal phosphate wasting. Recent molecular insight has put fibroblast growth factor (FGF-23) into the centre of pathophysiological considerations because of (i) overproduction (tumour-associated osteomalacia) or (ii) hypothetically, accumulation resulting from mutations causing resistance to processing or degradation (autosomal dominant hypophosphataemia) or (iii) loss-of-function of a protease (PHEX) interfering with FGF-23 breakdown (XLH). In oncogenic osteomalacia the treatment of choice is resection of the tumour. Recently, pharmacological treatment has also become possible, i.e. administration of octreotide. XLH and autosomal dominant hypophosphataemia must be managed by oral administration of phosphate and calcitriol. In patients with gastrointestinal intolerance to phosphate or with severely symptomatic bone disease, prolonged intravenous administration of Pi is necessary.
Assuntos
Hipofosfatemia Familiar , Hipofosfatemia , Fosfatos/metabolismo , Diagnóstico Diferencial , Fator de Crescimento de Fibroblastos 23 , Humanos , Hipercalcemia/complicações , Hipercalcemia/diagnóstico , Hipofosfatemia/etiologia , Hipofosfatemia/fisiopatologia , Hipofosfatemia/terapia , Hipofosfatemia Familiar/diagnóstico , Hipofosfatemia Familiar/metabolismo , Hipofosfatemia Familiar/terapia , Neoplasias/complicações , Neoplasias/diagnóstico , Osteomalacia/diagnóstico por imagem , Osteomalacia/metabolismo , Osteomalacia/terapia , RadiografiaAssuntos
Fosfatos/deficiência , Raquitismo/etiologia , Deficiências Nutricionais/complicações , Síndrome de Fanconi/complicações , Genes Dominantes , Humanos , Hipofosfatemia Familiar/complicações , Hipofosfatemia Familiar/genética , Hipofosfatemia Familiar/terapia , Neoplasias/complicações , Osteomalacia/diagnóstico , Osteomalacia/etiologia , Osteomalacia/genética , Osteomalacia/terapiaRESUMO
X-Linked hypophosphatemic rickets (XLH) is characterized by hypophosphatemia, rickets, and impaired growth. Despite oral phosphate and 1,25-dihydroxyvitamin D(3) treatment, many patients have suboptimal growth and bone healing. The aim of this study was to assess whether age at treatment onset impacts the outcome. Growth data, biochemistry, and radiographs of 19 well-controlled patients with XLH were analyzed retrospectively. Patients were divided into two groups based on the age at treatment onset (group 1, <1.0 yr; group 2, >or=1.0 yr). The median height z-score was higher in group 1 (n = 8) than in group 2 (n = 11) at treatment onset [-0.4 SD score (SDS) vs. -1.7 SDS; P = 0.001], at the end of the first treatment year (-0.7 SDS vs. -1.8 SDS; P = 0.009), throughout childhood (P > 0.05) and until predicted adult height (-0.2 SDS vs. -1.2 SDS; P = 0.06). The degree of hypophosphatemia was similar in both groups, but serum alkaline phosphatase remained higher in group 2 throughout childhood. Radiographic signs of rickets were more marked in group 2, but even patients with early treatment developed significant skeletal changes of rickets. These data suggest that treatment commenced in early infancy results in improved outcome in patients with XLH, but does not completely normalize skeletal development.